Disorders of Neuromuscular Transmission

Published on 12/04/2015 by admin

Filed under Neurology

Last modified 12/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3564 times

Chapter 78 Disorders of Neuromuscular Transmission

Normal muscle contraction and force production require the efficient transmission of an electrical impulse from a motor axon to the muscle fibers it innervates. The neuromuscular junction (NMJ), a specialized synapse with a complex structural and functional organization, is the site of electrochemical conversion of nerve impulses into muscle fiber action potentials. The NMJ is particularly vulnerable to autoimmune disorders caused by circulating immune factors (myasthenia gravis and Lambert-Eaton myasthenic syndrome), since it has no blood-nerve barrier. Genetic abnormalities and certain toxins may disrupt neuromuscular transmission (NMT) as well. Disorders of NMT produce several characteristic clinical syndromes, described in this chapter.

Myasthenia Gravis

Acquired myasthenia gravis (MG) is the most common primary disorder of NMT. In MG, the binding of autoantibodies to proteins, most commonly the acetylcholine receptor (AChR), disrupts normal NMT. This results in symptomatic muscle weakness that predominates in certain muscle groups and fluctuates in response to effort and rest. The basis for diagnosis is the recognition of a distinctive pattern of weakness on history and examination, and confirmation by diagnostic tests. Several potentially effective treatments are available, and treatment of most patients is effective with minimal long-term morbidity.

Epidemiology of Myasthenia Gravis

MG may begin at any age from infancy to very old age. Epidemiological studies report considerable variability in incidence and prevalence around the world (Meriggioli and Sanders, 2009). While methodological differences may explain some of this variability, biological and genetic factors may also play a role. Recent estimates indicate that the U.S. prevalence is approximately 20/100,000, 60,000 patients total (Phillips, 2004). Epidemiological studies have shown an increasing prevalence over the past 50 years, related to an increase in the frequency of diagnosis in elderly patients but also likely due to improved ascertainment, reduced mortality rates, and increased longevity of the population. Gender and age influence the incidence of MG; women are affected nearly three times more often than men before age 40, but the incidence is higher in males after age 50 and roughly equal during puberty. As the population ages, the average age at onset has increased correspondingly. More men than women are now affected, and the majority of MG patients in the United States are older than 50. Detailed population-based data on clinical and serological subtypes of MG (see Myasthenia Gravis Subtypes) are largely lacking.

Clinical Presentation of Myasthenia Gravis

Patients with MG seek medical attention for specific muscle weakness or dysfunction that typically worsens with activity and improves with rest. Although they may also have generalized fatigue or malaise, it is not usually the major or presenting complaint. Ptosis or diplopia is the initial symptom in approximately two-thirds of patients; nearly all will develop both within 2 years (Sanders and Massey, 2008). Difficulty chewing, swallowing, or talking is the initial symptom in one-sixth of patients, and limb weakness in 10%. Rarely, the initial weakness is limited to single muscle groups such as neck or finger extensors, hip flexors, or ankle dorsiflexors.

Myasthenic weakness typically fluctuates during the day, usually being least in the morning and worse as the day progresses, especially after prolonged use of affected muscles. Ocular symptoms may be intermittent in the early stages, typically becoming worse in the evening or while reading, watching television, or driving, especially in bright sunlight. Many patients find that dark glasses reduce diplopia and hide drooping eyelids. Jaw muscle weakness typically becomes worse during prolonged chewing, especially tough, fibrous, or chewy foods.

Careful questioning often reveals evidence of earlier unrecognized myasthenic manifestations, such as frequent purchases of new eyeglasses to correct blurred vision, avoidance of foods that became difficult to chew or swallow, or cessation of activities that require prolonged use of specific muscles, such as singing. Friends may have noted a sleepy or sad facial appearance caused by ptosis or facial weakness.

The course of disease is variable but usually progressive. Weakness remains restricted to the ocular muscles in approximately 10% to 15% of cases (see Ocular Myasthenia Gravis, later in this chapter), although a higher proportion has been reported in Asian populations (Meriggioli and Sanders, 2009). In the rest, weakness progresses to involve nonocular muscles during the first 3 years and ultimately involves facial, oropharyngeal, and limb muscles (generalized MG). Maximum weakness occurs during the first year in two-thirds of patients. Before the introduction of corticosteroids for treatment, approximately one-third of patients improved spontaneously, one-third became worse, and one-third died of the disease. Improvement, even remission, may occur early on but is rarely permanent (i.e., there is a subsequent relapse). Symptoms typically fluctuate over a relatively short period and then become more severe (active stage). Left untreated, an inactive stage follows the active stage, in which fluctuations in strength still occur but are attributable to fatigue, intercurrent illness, or other identifiable factors. After many years, untreated weakness becomes fixed, and the most severely involved muscles are frequently atrophic (burnt-out stage). Factors that worsen myasthenic symptoms are emotional upset, systemic illness (especially viral respiratory infections), hypothyroidism or hyperthyroidism, pregnancy, the menstrual cycle, drugs affecting NMT (see Treatment of Associated Diseases and Medications to Avoid, later in this chapter), and fever.

Physical Findings in Myasthenia Gravis

Perform the examination so as to detect variable weakness in specific muscle groups. Assess strength repetitively during maximum effort and again after rest. Performance on such tests may also fluctuate in diseases other than MG, especially if effort varies or testing causes pain. The symptoms of MG do not always vary, particularly in long-standing disease, which can make the diagnosis difficult.

Ocular Muscles

imageMost MG patients have weakness of ocular muscles (Box 78.1). (Videos of MG-related ocular phenomena [Videos 78.1 and 78.2] can be found at www.expertconsult.com.) Asymmetrical weakness of several muscles in both eyes is typical, the medial rectus being more frequently and usually more severely involved. The pattern of weakness is not localizable to lesions of one or more nerves, and the pupillary responses are normal. Ptosis is usually asymmetrical (Fig. 78.1) and varies during sustained activity. To compensate for ptosis, chronic contraction of the frontalis muscle produces a worried or surprised look. Unilateral frontalis contraction is a clue that the lid elevators are weak on that side (see Fig. 78.1). When mild, ocular weakness may not be obvious on routine examination and appear only upon provocative testing (i.e., sustained upward gaze). Eyelid closure is usually weak, even when strength is normal in all other facial muscles, and may be the only residual weakness in otherwise complete remission. This is usually asymptomatic unless it is severe enough to allow soap or water in the eyes during bathing. With moderate weakness of these muscles, the eyelashes are not “buried” during forced eye closure (Fig. 78.2). Fatigue in these muscles may result in slight involuntary opening of the eyes as the patient tries to keep the eyes closed; this is called the peek sign (see Fig. 78.2).


Fig. 78.2 “Peek” sign in myasthenia gravis. During sustained forced eyelid closure, patient is unable to bury his eyelashes (left), and after 30 seconds, he is unable to keep the lids fully closed (right).

(Reproduced from Sanders, D.B., Massey, J.M., 2008. Clinical features of myasthenia gravis, in: Engel, A.G. (Ed.), Handbook of Clinical Neurology, vol 91: Neuromuscular Junction Disorders. Elsevier, Amsterdam, pp. 229-252 [Fig. 5], by permission.)

Limb Muscles

Weakness begins in limb or axial muscles in about 20% of MG patients (Kuks and Oosterhuis, 2004). Any trunk or limb muscle may be weak, but some are more often affected than others. Neck flexors are usually weaker than neck extensors, and the deltoids, triceps, and extensors of the wrist and fingers and ankle dorsiflexors are frequently weaker than other limb muscles. Rarely, MG presents initially with focal weakness in single muscle groups, such as a “dropped head syndrome” due to severe neck extensor weakness or isolated vocal cord or respiratory muscle weakness. In untreated patients with long-standing disease, weakness may be fixed, and severely involved muscles may be atrophic, giving the appearance of a chronic myopathy; this is particularly likely in muscle-specific tyrosine kinase (MuSK) antibody–positive MG (see MuSK Antibody Myasthenia Gravis, later in this chapter).

Immunopathology of Myasthenia Gravis

The neuromuscular transmitter, acetylcholine (ACh), releases from the motor nerve terminal in discrete packages (quanta) that cross the synaptic cleft and bind to receptors (AChR) on the folded muscle end-plate membrane. Muscle contraction results when ACh-AChR binding depolarizes the end-plate region and then the muscle membrane. Acetylcholinesterase attached to the postsynaptic muscle membrane hydrolyzes the released ACh, terminating its action and preventing prolonged muscle depolarization.

In about 80% to 85% of MG patients, weakness results from the effects of circulating anti-AChR antibodies. These antibodies bind to AChR on the terminal expansions of the junctional folds (Fig. 78.3) (Engel et al., 1977a) and cause complement-mediated destruction of the folds, accelerated internalization and degradation of AChR, and in some cases, they block ACh-AChR binding. Destruction of the junctional folds results in distortion and simplification of the postsynaptic region (see Fig. 78.4) and loss of functional AChR (Engel et al., 1977b). This leads to NMT failure and muscle weakness. MG is a paradigm for an antibody-mediated disease: the physiological abnormality is passively transferable by injection of MG immunoglobulin (Ig)G into mice, and clinical improvement follows removal of circulating antibodies by plasma exchange (see Treatment of Myasthenia Gravis, later in this chapter).


Fig. 78.3 Localization of immunoglobulin G (IgG) at a neuromuscular junction in acquired myasthenia gravis. The immune deposits appear on short segments of some junctional folds and on degenerate material in the synaptic space.

(Reproduced from Engel, A.G., Lambert, E.H., Howard, F.M., 1977a. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlation. Mayo Clin Proc 52, 267-280, by permission.)


Fig. 78.4 Ultrastructural localization of acetylcholine receptor (AChR) at the muscle end-plate in a control subject (A) and in a patient with generalized myasthenia gravis (B). The AChR staining seen in A is virtually absent in B, in which only short segments of simplified postsynaptic membrane react.

(Reproduced from Engel, A.G., Lindstrom, J.M., Lambert, E.H., et al., 1977b. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and its experimental autoimmune model. Neurology 27, 307-315 [Fig. 3A/B], by permission.)

T-lymphocytes play a pivotal role in the initiation and maintenance of the autoimmune response against the AChR complex. However, the precise mechanism by which this response initiates and is maintained is incompletely understood. Activation of T cells is through the T-cell receptor by major histocompatibility complex (MHC) class II molecules bound with antigenic peptide, but full activation requires the presence of a second signal (costimulatory molecules). Potentially autoreactive T cells are normally controlled by a variety of immune regulatory mechanisms, including regulatory T cells, which are likely deficient or dysfunctional in MG.

Patients with MG have increased numbers of CD4+ T cells, which regulate the production of AChR antibody (AChR-Ab). The α subunit of AChR contains the majority of T-cell recognition sites. These recognition sites may be different from those of the main immunogenic region that binding antibodies recognize. Sensitization to CD4+ T-cells spreads across the AChR complex as the disease progresses and most MG patients have T cells that recognize multiple epitopes on the AChR α-subunit (Conti-Fine et al., 1997). This epitope spread drives the synthesis of anti-AChR antibodies and accounts for the large and varied antibody repertoire of the myasthenic patient.

Approximately 10% of MG patients (up to 50% of anti-AChR-negative, generalized MG patients) have circulating antibodies to MuSK, a surface membrane component essential in the development of the neuromuscular junction. These anti-MuSK antibodies adversely affect the maintenance of AChR clustering at the muscle end-plate, leading to reduced numbers of functional AChRs. The precise pathophysiology of the weakness and prominent muscle atrophy in anti-MuSK MG is unknown. Muscle biopsy studies have shown little AChR loss, but no detailed studies of NMT in the most affected muscles are available. The events leading to autosensitization to MuSK are unknown, but the thymus gland is probably not involved.

The remaining so-called double-seronegative patients have no known antibodies by conventional assays, even though they may improve with immunosuppressive treatments, plasma exchange, or even thymectomy.

Recently, low-affinity IgG antibodies have been found in about two-thirds of MG patients who were seronegative using conventional anti-AChR and anti-MuSK antibody assays (Leite et al., 2008). These antibodies bind to AChRs that have been clustered into high-density arrays, suggesting that they have relatively low affinity and cannot bind strongly to AChR in solution but do bind to immobilized AChRs in a native conformation.

Myasthenia Gravis Subtypes

A number of MG subtypes (Table 78.1) may be identified based on the clinical presentation, age of onset, autoantibody profile, and thymic pathology (Meriggioli and Sanders, 2009). Interestingly, these subtypes appear to have unique genetic associations, strengthening the concept of distinct clinical entities and disease mechanisms.

Ocular Myasthenia Gravis

Ptosis and/or diplopia are the initial symptoms of MG in up to 85% of patients (Grob et al., 2008), and almost all patients have both symptoms within 2 years of disease onset. Myasthenic weakness that remains limited to the ocular muscles is termed ocular myasthenia gravis (OMG) and accounts for approximately 10% to 15% of all MG in Caucasian populations. If weakness remains limited to the ocular muscles after 2 years, there is a 90% likelihood that the disease will not generalize. OMG is more common in Asian populations (up to 58% of all MG patients) (Zang et al., 2007).

Confirmation of the diagnosis of OMG may be a challenge, as RNS studies and anti-AChR antibodies are often negative, and single-fiber electromyography (SFEMG) testing may be required.

MuSK-Antibody Myasthenia Gravis

Antibodies to MuSK have been reported in up to 50% of patients with GMG who lack AChR antibodies (Guptill and Sanders, 2010) and have recently been reported in OMG as well (Bau et al., 2006; Caress et al., 2005). The reported incidence of MuSK-antibody myasthenia gravis (MMG) varies among geographic regions, the highest being closer to the equator and the lowest closer to the poles (Vincent and Lang, 2006). Genetic or environmental factors (or both) presumably play a role in these differences. MMG predominantly affects females and begins from childhood through middle age. In some patients, the clinical findings are indistinguishable from anti-AChR-positive MG, with fluctuating ocular, bulbar, and limb weakness. However, many MMG patients have predominant weakness in cranial and bulbar muscles, frequently with marked atrophy of these muscles (Fig. 78.5). Others have prominent neck, shoulder, and respiratory weakness, with little or no involvement of ocular or bulbar muscles. Electrodiagnostic abnormalities may not be as widespread as in other forms of MG, and it may be necessary to examine different muscles to demonstrate abnormal NMT (Stickler et al., 2005). The potentially more limited distribution of physiological abnormalities also may limit the interpretation of microphysiological and histological studies in MMG, inasmuch as the muscles usually biopsied for these studies may be normal.

Many MMG patients do not improve with cholinesterase inhibitors (ChEIs); some actually become worse, and many have profuse fasciculations with these medications (Hatanaka et al., 2005). Disease severity tends to be worse, but most improve dramatically with PLEX or corticosteroids (Sanders et al., 2003). More immunosuppression is typically necessary, though long-term outcome is generally good (Guptill and Sanders, 2010). Thymic changes are absent or minimal (Lauriola et al., 2005; Leite et al., 2005), and the role of thymectomy in MMG is not yet clear (Guptill and Sanders, 2010; Sanders et al., 2003). The diagnosis of MMG may be elusive when the clinical features, electrodiagnostic findings, and response to ChEIs differ from typical MG.

Genetics of Myasthenia Gravis

The transmission of MG is not by classic Mendelian inheritance, but family members of patients are approximately 1000 times more likely to develop the disease than the general population. In addition, 33% to 45% of asymptomatic first-degree family members show jitter on SFEMG testing, and anti-AChR antibodies are slightly elevated in up to 50%. These observations suggest that there is a genetically determined predisposition to develop MG.

Several correlations exist between MG and the human leukocyte antigen (HLA) genes. Certain HLA types (-DR2, -DR3, -B8, -DR1) predispose to MG (see Table 78.1), whereas others may offer resistance to disease. HLA-B8, -DR2, and -DR3 types occur more commonly in patients with EOMG; HLA-B7 and -DR2 in LOMG; and HLA-DR1 in OMG (see Table 78.1). MMG is associated with HLA-DR14-DQ5 (Niks et al., 2006). Different HLA associations have been reported in Asian MG patients, including an association of OMG with HLA-BW46 in Chinese patients (Meriggioli and Sanders, 2009). Non-HLA genes (PTPN22, FCGR2, CHRNA1) have also been found to be associated with MG; some are also associated with other autoimmune diseases and thus may represent a nonspecific susceptibility to autoimmunity. An exception to this is the CHRNA1 gene, which encodes the α subunit of the AChR and may provide pathogenetic clues specific for MG (Meriggioli and Sanders, 2009).

Diagnostic Procedures in Myasthenia Gravis

Edrophonium Chloride Test

Edrophonium and other ChEIs impede the enzymatic breakdown of ACh by inhibiting the action of acetylcholinesterase, thus allowing ACh to diffuse more widely throughout the synaptic cleft and to have a more prolonged interaction with AChR on the postsynaptic muscle membrane. This facilitates repeated interaction of ACh with the reduced number of AChRs and results in greater end-plate depolarization. Weakness from abnormal NMT characteristically improves after administration of ChEIs, and this is the basis of the diagnostic edrophonium test.

The most important consideration in performance of the edrophonium test is the choice of endpoint. Only unequivocal improvement in strength of an affected muscle is acceptable as a positive result. For this reason, resolution of eyelid ptosis, improvement in strength of a single paretic extraocular muscle, or clear improvement of dysarthria have been proposed as the only truly valid endpoints because observed function in these muscles is largely independent of fluctuating effort (Fig. 78.6). Interpret changes in strength of other muscles cautiously, especially in a suggestible patient.


Fig. 78.6 Edrophonium test in myasthenia gravis. Before testing (left) there is marked ptosis of the left lid and lateral deviation of the left eye, and the jaw must be supported. Within 5 seconds after injection of 0.1 mg edrophonium (right), function of both lids and left medial rectus are improved.

(Reproduced from Sanders, D.B., Massey, J.M., 2008. Clinical features of myasthenia gravis, in: Engel, A.G. (Ed.), Handbook of Clinical Neurology, vol 91: Neuromuscular Junction Disorders. Elsevier, Amsterdam, pp. 229-252 [Fig. 10], by permission.)

The edrophonium test is reported to be positive in 60% to 95% of patients with OMG and in 72% to 95% with GMG (Pascuzzi, 2003). Improvement after edrophonium is not unique to MG; it is also seen in congenital myasthenic syndromes, the Lambert-Eaton syndrome, intracranial aneurysms, brainstem lesions, cavernous sinus tumors, end-stage renal disease, and in muscle diseases affecting the ocular muscles.

imageThe optimal dose of edrophonium varies among patients and cannot be predetermined. In a study of OMG, the mean dose of edrophonium that gave a positive response was 3.3 mg for ptosis and 2.6 mg for ocular muscle dysfunction (Kupersmith et al., 2003). The lowest effective dose can be determined by injecting small incremental doses up to a maximum total of 10 mg. Inject an initial test dose of 2 mg, and monitor the response for 60 seconds. Subsequent injections of 3 and 5 mg may then be given, but if clear improvement is seen within 60 seconds after any dose, the test is positive, and no further injections are necessary (see Video 78.1). Weakness that develops or worsens after injection of 10 mg or less also indicates an NMT defect, as this dose will not weaken normal muscle.

Common side effects of edrophonium are increased salivation and sweating, nausea, stomach cramps, and fasciculations. Serious complications (bradyarrhythmia or syncope) have been reported in only 0.16% of edrophonium tests (Ing et al., 2005). These symptoms generally resolve with rest in the supine position. Atropine (0.4-2 mg) should be available for intravenous (IV) injection if bradycardia is severe.

Some patients who do not respond to IV edrophonium may improve after injection of neostigmine methylsulfate, 0.5 mg intramuscularly (IM) or subcutaneously (SQ), which has a longer duration of action. Onset of action after IM injection is 5 to 15 minutes. The longer duration of action is particularly useful in children.

Autoantibodies in Myasthenia Gravis

Acetylcholine Receptor Antibodies

Assays measuring antibodies that react with AChR proteins are generally regarded as specific serological markers for MG. The most widely utilized test for MG is the AChR-Ab binding assay. This assay tests serum for binding to purified AChR from human skeletal muscle labeled with radioiodinated α-bungarotoxin. The reported sensitivity of this assay is approximately 85% for GMG and 50% for OMG (Stålberg et al., 2010). Nearly all thymomatous MG patients have elevated AChR antibodies.

Finding elevated AChR antibodies in a patient with compatible clinical features essentially confirms the diagnosis of MG, but normal antibody measurements do not exclude the disease. Assays for AChR antibodies may be normal at symptom onset and become abnormal later in the disease, so repeat testing is appropriate when values obtained within 6 to 12 months of symptom onset were normal.

AChR antibody levels tend to be lower in patients with ocular or mild generalized MG, but these values vary widely among patients with similar degrees of weakness and do not predict the severity of disease in individual patients. Antibody levels fall in most patients after immunosuppressive treatment and may even become normal in some. However, the AChR antibody level is not a consistent marker of overall response to therapy and may actually rise in some patients as their symptoms improve.

False-positive AChR-Ab tests are rare but have been reported in autoimmune liver disease, systemic lupus erythematosus (SLE), inflammatory neuropathies, amyotrophic lateral sclerosis, penicillamine-treated patients with rheumatoid arthritis, patients with thymoma but without MG, and in first-degree relatives of patients with acquired autoimmune MG.

Another assay for AChR antibodies measures inhibition of binding of radiolabeled α-bungarotoxin to the AChR. This technique measures antibody directed against the ACh binding site on the α subunit of the AChR. In most patients, relatively few of the circulating antibodies recognize this site, resulting in a lower sensitivity for this assay. These blocking antibodies occur in less than 1% of MG patients who do not have measurable binding antibodies and thus have limited diagnostic value.

AChR antibodies cross-link the AChRs in the membrane and increase their rate of degradation. The AChR-modulating antibody assay measures the rate of loss of labeled AChR from cultured human myotubes. About 10% of MG patients who do not have elevated binding antibodies have AChR-modulating antibodies. Many patients with thymomatous MG have high levels of AChR-modulating antibodies, often exceeding 90% loss of AChR (Vernino and Lennon, 2004).

Antistriational Muscle Antibodies

Antistriational muscle antibodies (StrAbs), which react with contractile elements of skeletal muscle, were the first autoantibodies discovered in MG. These antibodies recognize muscle cytoplasmic proteins (titin, myosin, actin, and ryanodine receptors), and are found in 75% to 85% of patients with thymomatous MG. Titin is a very large filamentous protein essential for muscle structure, function, and development; most of the thymoma-associated antibodies against striated muscle are against titin. The ryanodine receptor (RyR) is a calcium release channel in the sarcoplasmic reticulum of skeletal muscle. Anti-RyR antibodies occur in 75% of MG patients with thymoma but may also be present in LOMG patients without thymoma.

StrAbs are not pathogenic and are also found in one-third of patients with thymoma who do not have MG and in one-third of MG patients without thymoma. They are more frequent in older MG patients and in those with more severe disease, suggesting that disease severity is related to a more vigorous humoral response against multiple muscle antigens (Romi et al., 2005).

StrAbs are rarely elevated in MG in the absence of AChR antibodies and are therefore of limited use in confirming the diagnosis. The main clinical value of StrAbs is in predicting thymoma: 60% of patients with MG with onset before age 50 who have elevated StrAbs have thymoma. However, titin and other striational antibodies are detectable in up to 50% of elderly patients with non-thymomatous MG, so these antibodies are less helpful as predictors of thymoma in patients older than age 60. Elevated StrAbs are also present in autoimmune liver disease and infrequently seen in Lambert-Eaton syndrome and in primary lung cancer.

Electrodiagnostic Testing in Myasthenia Gravis

Repetitive nerve stimulation (RNS) is the most commonly used electrophysiological test of NMT. At low rates of stimulation (2-5 Hz), RNS depletes the store of readily releasable ACh at diseased motor end-plates, causing failure of NMT. Characteristically in MG, there is a decrementing response of at least 10% to trains of 2- to 3-Hz stimulation (see Chapter 32B). This may be present at baseline or after a period of exercise (postactivation exhaustion). Although a seemingly simple test, careful attention to proper technique is important to avoid technical errors. The sensitivity of RNS for diagnosing MG reportedly ranges from 53% to 100% in GMG and 10% to 48% in OMG (Meriggioli and Sanders, 2004; Stålberg et al., 2010). RNS is more likely to be abnormal in a proximal or facial muscle and in clinically weak muscles. For maximal diagnostic yield, test several muscles, particularly those that are weak. If RNS is normal and there exists a high suspicion for an NMJ disorder, perform SFEMG of at least one symptomatic muscle.

SFEMG (see Chapter 32B) is the most sensitive clinical test of NMT and shows increased jitter in some muscles in almost all patients with MG (Stålberg et al., 2010). Jitter is greatest in weak muscles but is usually abnormal even in muscles with normal strength. Sixty percent of patients with OMG show increased jitter in a limb muscle, but this does not predict the subsequent development of generalized myasthenia.

In the rare patient who has weakness restricted to a few limb muscles, only a weak muscle may show abnormal jitter. This is particularly true in some patients with MMG (Stickler et al., 2005) (see MuSK-Antibody Myasthenia Gravis, earlier).

Increased jitter is a nonspecific sign of abnormal NMT and can occur in other motor unit diseases. Therefore, when jitter is increased, perform other electrodiagnostic tests to exclude neuronopathy, neuropathy, and myopathy. Normal jitter in a weak muscle excludes abnormal NMT as the cause of weakness.

Recently, measuring jitter with concentric needle electrodes (CNE) has been proposed as an alternative to the specially designed (reusable) single-fiber electrode (Stålberg and Sanders, 2009). Interpret the results with caution, particularly in borderline cases, as signals recorded with the CNE may represent the summation of more than one single-fiber action potential, which will decrease the apparent jitter.

Comparison of Diagnostic Techniques in Myasthenia Gravis

Plan diagnostic testing based on the clinical presentation and distribution of weakness (Table 78.2). The edrophonium test is often diagnostic in patients with ptosis or ophthalmoparesis but is less useful in assessing other muscles. The presence of serum AChR or anti-MuSK antibodies virtually ensures the diagnosis of MG, but their absence does not exclude it. RNS confirms impaired NMT but is frequently normal in mild or purely ocular disease. Almost all patients with MG have increased jitter, and normal jitter in a weak muscle excludes MG as the cause of the weakness. Neither electrodiagnostic test is specific for MG, because increased jitter, even abnormal RNS, occurs in other motor unit disorders that impair NMT.